Human–SCID mouse chimeric models for the evaluation of anti-cancer therapies
- 1 July 2001
- journal article
- review article
- Published by Elsevier BV in Trends in Immunology
- Vol. 22 (7), 386-393
- https://doi.org/10.1016/s1471-4906(01)01943-3
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using125I-labeled anti-endoglin monoclonal antibodiesInternational Journal of Cancer, 1999
- THE SCID MOUSE REACTION TO HUMAN PERIPHERAL BLOOD MONONUCLEAR LEUKOCYTE ENGRAFTMENTTransplantation, 1995
- Survival of human prostate carcinoma, benign hyperplastic prostate tissues, and IL‐2‐activated lymphocytes in SCID miceThe Prostate, 1995
- Inhibition of Human Colon Cancer Growth by Antibody-Directed Human LAK Cells in SCID MiceScience, 1993
- Lymphoproliferative disease in human peripheral blood mononuclear cell-injected SCID mice. I. T lymphocyte requirement for B cell tumor generation.The Journal of Experimental Medicine, 1992
- Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: Growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cellsCancer Immunology, Immunotherapy, 1992
- Human‐mouse lymphoid chimeras: host‐vs.‐graft and graft‐vs.‐host reactionsEuropean Journal of Immunology, 1992
- Human mature T cells that are anergic in vivo prevail in SCID mice reconstituted with human peripheral blood.The Journal of Experimental Medicine, 1992
- The scid mutation in mice causes a general defect in DNA repairNature, 1990
- Establishment of a Human Cutaneous T-Cell Lymphoma in C.B-17 SCID MiceJournal of Investigative Dermatology, 1990